$36.54
3.13% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US92346J1088
Symbol
VCEL

Vericel Corporation Stock price

$35.43
-4.50 11.27% 1M
-22.08 38.39% 6M
-19.48 35.48% YTD
-10.02 22.05% 1Y
+8.35 30.83% 3Y
+19.32 119.93% 5Y
+32.18 990.15% 10Y
-434.97 92.47% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.81 2.24%

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.7b
Net debt
positive
Cash
$116.9m
Shares outstanding
50.4m
Valuation (TTM | estimate)
P/E
253.1 | 141.8
P/S
7.2 | 6.1
EV/Sales
6.7 | 5.7
EV/FCF
negative
P/B
5.8
Financial Health
Equity Ratio
67.5%
Return on Equity
3.6%
ROCE
0.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$249.1m | $291.9m
EBITDA
$9.5m | $72.4m
EBIT
$1.2m | $7.6m
Net Income
$7.1m | $12.6m
Free Cash Flow
$-8.3m
Growth (TTM | estimate)
Revenue
16.1% | 23.0%
EBITDA
705.9% | 622.8%
EBIT
131.2% | 69.2%
Net Income
800.0% | 21.6%
Free Cash Flow
-279.0%
Margin (TTM | estimate)
Gross
73.5%
EBITDA
3.8% | 24.8%
EBIT
0.5%
Net
2.9% | 4.3%
Free Cash Flow
-3.3%
More
EPS
$0.1
FCF per Share
$-0.2
Short interest
13.8%
Employees
357
Rev per Employee
$660.0k
Show more

Is Vericel Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Vericel Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Vericel Corporation forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Vericel Corporation forecast:

Buy
93%
Hold
7%

Financial data from Vericel Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
249 249
16% 16%
100%
- Direct Costs 66 66
4% 4%
27%
183 183
21% 21%
73%
- Selling and Administrative Expenses 157 157
20% 20%
63%
- Research and Development Expense 25 25
3% 3%
10%
9.51 9.51
706% 706%
4%
- Depreciation and Amortization 8.32 8.32
66% 66%
3%
EBIT (Operating Income) EBIT 1.19 1.19
131% 131%
0%
Net Profit 7.11 7.11
800% 800%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Vericel Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vericel Corporation Stock News

Positive
The Motley Fool
7 days ago
Vericel Q2 Revenue Jumps 20%
Neutral
Seeking Alpha
12 days ago
Vericel Corporation (NASDAQ:VCEL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Dominick C. Colangelo – CEO, President & Director Eric Burns – Vice President of Finance & Investor Relations Joseph Anthony Mara – CFO & Treasurer Analysts Caitlin Cronin - Canaccord Genuity Corp., Research Division Mason Owen Carrico - Stephens Inc., Research Division Richard Samuel Newitte...
Neutral
GlobeNewsWire
12 days ago
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Co...
More Vericel Corporation News

Company Profile

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Head office United States
CEO Dominick Colangelo
Employees 357
Founded 1989
Website vcel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today